7 results about "Aciclovir" patented technology

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The invention relates to the technical field of biological medicines, relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating viruses, and in particular relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating herpes simplex viruses. The herpes simplex virus disclosed by the invention is one or two of HSV-1 (Herpes Simplex Virus) or HSV-2 (Herpes Simplex Virus). The caerin1.1, the caerin1.9 or the composition of the caerin1.1 and the caerin1.9 disclosed by the invention has different degrees of prevention and treatment effects on HSV-1 and / or HSV-2, and has a more obvious effect on the HSV-2. Compared with an existing antiviral drug, the compound has a better effect of preventing and treating viruses, the prevention effect is obviously better than that of acyclovir, the application range is wide, and potential toxic and side effects are low.

The invention relates to the field of antiviral drugs, in particular to application of a miRNA (micro Ribonucleic Acid) simulant in preparation of anti-I-type herpes simplex virus drugs. The miRNA simulant provided by the invention is an analogue of I-type herpes simplex virus coding miR-H5-5p and is double-stranded RNA synthesized by a chemical method, the molecular weight of the miRNA simulant is about 13300 Daltons, and the sequence of the miRNA simulant is shown as SEQ ID NO. 1 or SEQ ID NO. 2. The miRNA simulant disclosed by the invention can show remarkable activity of resisting the acyclovir-resistant I-type herpes simplex virus in HEK293T cells and Vero cells, so that the miRNA simulant can be used for preparing the medicine for resisting the acyclovir-resistant I-type herpes simplex virus.

The present application relates to a kind of sustained-release acyclovir tablets and its preparation process, belong to the technical field of medicine.The acyclovir tablet provided by the present application has immediate-release layer and sustained-release layer, immediate-release layer can be quickly released, rapidly increase the blood concentration in human body;Sustained-release layer has multi-stage drug release characteristics, it includes three kinds of sustained-release particles, which can effectively delay, positioning release drug, constantly supplement the blood concentration in body, maintain stable blood concentration, can effectively sustain release up to about 12h, and can maintain relatively stable blood concentration within 12 hours, reduce the frequency of drug taking, improve patient compliance, suitable for the patient with herpes simplex virus infection who needs long-term treatment.

This invention provides a traditional Chinese medicine composition for treating herpes zoster, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The active ingredients of the traditional Chinese medicine composition include the following two parts: (1) Traditional Chinese medicine active ingredients: by weight, prepared from the following traditional Chinese medicinal materials: 10-15 parts of Isatis root; 10-15 parts of Isatis leaf; 10-15 parts of Astragalus; 8-12 parts of Angelica sinensis; 8-12 parts of white peony root; 6-10 parts of Ligusticum chuanxiong; 5-8 parts of safflower; 5-8 parts of red peony root; 5-8 parts of Salvia miltiorrhiza; 4-7 parts of cicada slough; 4-7 parts of earthworm; 4-7 parts of Saposhnikovia divaricata; and 3-5 parts of licorice; (2) Western medicine active ingredients: composed of acyclovir and famciclovir in a weight ratio of 1:1-3. This invention is a traditional Chinese and Western medicine combined drug developed based on the traditional Chinese medicine treatment of herpes zoster and combined with modern pharmaceutical technology. It adopts bio-enzymatic hydrolysis technology and nano-level drug delivery system, which significantly improves the bioavailability and targeting of the drug. It has a unique therapeutic effect on shingles, and its advanced preparation process results in significant efficacy, short onset time, convenient administration, few adverse reactions, safety and effectiveness. It can also prevent and relieve postherpetic neuralgia, providing a new option for the treatment of shingles.

This invention discloses a compound containing diacylpropidine, its preparation method, and its applications. Remdesivir, acyclovir, vidarabine, and stavudine, along with succinic anhydride, are reacted in dichloromethane to obtain an intermediate containing a monocarboxylic acid; or remdesivir, acyclovir, vidarabine, and stavudine, along with pimelic acid, are condensed in EDC·HCl to obtain an intermediate containing a monocarboxylic acid; a diacylpropidine-containing linker is then condensed with the intermediate containing the monocarboxylic acid in EDC·HCl to obtain a compound containing diacylpropidine. This compound can form covalent bonds with target proteins, achieving irreversible binding, providing a new mechanism of action and binding mode, improving the binding efficacy and duration of action of small molecule inhibitors, and enhancing the intensity and duration of drug action.

The present application relates to the field of antiviral drugs, and particularly relates to application of miRNA mimics in preparation of drugs for resisting type I herpes simplex virus, and provides the miRNA mimics, which is an analogue of miR-H5-5p coded by type I herpes simplex virus, is double-stranded RNA synthesized by a chemical method, has a molecular weight of about 13300 Dalton, and sequences are shown as SEQ ID NO. 1 and SEQ ID NO. 2. The miRNA mimics can show significant activity of resisting type I herpes simplex virus with acyclovir resistance in HEK293T cells and Vero cells, and shows that the miRNA mimics can be used for preparing drugs for resisting type I herpes simplex virus with acyclovir resistance.